Table 1.
Baseline clinical characteristics of the population
| Total cohort (n = 130) | |
|---|---|
| Age (years) | 67.3 (60.3–73.3) |
| Gender (male) | 104 (80) |
| Ischaemic aetiology | 75 (58) |
| NYHA III–IV | 113 (87) |
| LBBB | 108 (83) |
| QRS-duration (ms) | 163.0 (140.5–184.1) |
| Persistent AF | 37 (28) |
| BMI (kg/m2) | 27.0 (24.0–30.0) |
| Diabetes | 48 (37) |
| Hypertension | 71 (55) |
| BB | 117 (90) |
| ACEi/ARB | 124 (95) |
| Diuretics | 106 (82) |
| Digitalis | 39 (30) |
| Amiodarone | 39 (30) |
| LVEF (%) | 27.5 (23.0–33.0) |
| LVEDV (mL) | 312.6 (250.6–361.2) |
| LVESV (mL) | 218.2 (153.6–276.3) |
| Issues identified on the EQ-5D questionnaire | |
| Mobility | 70 (54) |
| Self-care | 11 (8) |
| Usual activities | 62 (48) |
| Pain/discomfort | 86 (66) |
| Anxiety/depression | 50 (38) |
| VAS (%) | 50.0 (35.0–65.0) |
Data are expressed as median (interquartile range) for continuous variables and as n (%) for categorical variables.
ACEi/ARB, angiotensin convertase inhibitor/angiotensin receptor blocker; BB, beta-blocker; LBBB, left bundle branch block; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MI, mitral insufficiency; NYHA, New York Heart Association Classification; VAS, visual analogue scale.